Could atrial natriuretic peptide be a useful drug therapy for high-risk patients after cardiac surgery?

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Post-cardiac surgery patients often require diuretic therapy.
• Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are endogenous natriuretic hormones with diuretic properties.
• Evaluating novel diuretic alternatives is crucial for optimizing patient recovery.

Purpose of the Study:

• To assess the efficacy of ANP and BNP as alternative diuretics in patients following cardiac surgery.
• To synthesize the best available evidence from randomized controlled trials (RCTs) on natriuretic peptides in this patient population.

Main Methods:

• A systematic literature search identified over 250 papers.
• Eight RCTs were selected as the best evidence to address the clinical question.
• Data on patient groups, study types, and relevant outcomes were tabulated.

Main Results:

• RCTs demonstrated consistent diuretic effects, including increased creatinine clearance and urine volume.
• Natriuretic peptides reduced the need for conventional diuretics and lowered postoperative urea and creatinine levels.
• Reduced decreases in glomerular filtration rate (GFR) were observed compared to placebo in patients with both normal and impaired renal function.
• Two studies reported a reduction in atrial fibrillation (AF) incidence and lower renin/aldosterone levels.
• The NAPA trial showed shorter ICU stay and reduced early mortality with nesiritide in CABG patients with LV dysfunction.

Conclusions:

• ANP and BNP exhibit significant diuretic effects and renoprotective properties in post-cardiac surgery patients.
• These peptides may offer an advantage over conventional diuretics, potentially improving renal outcomes.
• Further research, particularly large-scale trials like NAPA, is warranted to confirm benefits like reduced mortality and shorter ICU stays.